Key facts
- Notable investors include Hangzhou Capital, Hangzhou Huafang Chuangliang Investment Management, Holley Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Resight Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Resight Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Resight Therapeutics
Manufacturer of a cell-therapy drug intended to address unmet needs in eye-disease treatment. The company offers proprietary iPSC-differentiation and AI-compound reprogramming technologies, enabling ophthalmology researchers and clinicians to access novel regenerative therapies that restore vision.
- Sector
- Healthcare
- HQ
- Shaoxing, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Resight Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Resight Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Resight Therapeutics in its N-PORT filings yet. We sweep new filings monthly.